Cancer Institute and Hospital, Chinese Academy of Medical Sciences: Adenocarcinoma trials

The registry lists 11 Adenocarcinoma studies with Cancer Institute and Hospital, Chinese Academy of Medical Sciences as lead sponsor. 8 are open to participants now and 0 have results posted.

Phase 1 2Phase 2 6No phase 4(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Albumin-Bound Paclitaxel and Gemcitabine With or Without S-1 as First-Line Treatment for Advanced Pancreatic CancerRecruitingNCT06789679Phase 2
• QL1706 Plus Chemotherapy With AG Regime as First-line Treatment of Advanced PDACNot yet recruitingNCT06750861Phase 2
• Right Versus Left Thoracic Surgical Approaches for Siewert II Gastroesophageal Junction AdenocarcinomaRecruitingNCT06644352Not applicable
• Furmonertinib Combined With Anlotinib in Lung Adenocarcinoma Patients With EGFR Mutations and Brain MetastasesNot yet recruitingNCT06483672Phase 2
• Quantitative Nodal Burden as a Determinant Identifying Ampullary Adenocarcinoma Patients Benefiting From Adjuvant ChemotherapyRecruitingNCT06435767
• NALIRI-XELOX+AK104 for First-line Treatment of Advanced PDACRecruitingNCT06405490Phase 2
• Camrelizumab Combined With Chemotherapy and Radiotherapy Perioperative Treatment of Esophageal Gastric Junction AdenocarcinomaRecruitingNCT06163729Phase 2
• The Sequential Combination of FOLFOX and Toripalimab for Perioperative Immuno-Oncology Therapy of HER2-negative Adenocarcinoma of the Esophagogastric Junction (Siewert I/II):Not yet recruitingNCT05986227Phase 1/2
• Neo-Sequence 1: Neoadjuvant Chemotherapy With or Without Antiangiogenesis and Sequential Immunotherapy for HER2-negative MMR-proficient Locally Advanced Gastric or Gastroesophageal AdenocarcinomaCompletedNCT05540145
• Translational Research on Locally Advanced Pancreatic AdenocarcinomaStatus unknownNCT03009253Not applicable
• Apatinib Plus Docetaxel as 2nd Line Treatment in Patients With Advanced Lung Adenocarcinoma Harboring Wild-type EGFRStatus unknownNCT02691871Phase 1